JP2016533373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016533373A5 JP2016533373A5 JP2016524100A JP2016524100A JP2016533373A5 JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5 JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016524100 A JP2016524100 A JP 2016524100A JP 2016533373 A5 JP2016533373 A5 JP 2016533373A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tumor
- pancreatic cancer
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *[C@]1O[C@@](*)CN(Cc2ccc(C=C[C@@]3NNc4c3ccc([C@](C3)[C@]3(c3cc(*)ccc3N3*=I)C3=O)c4)cc2)C1 Chemical compound *[C@]1O[C@@](*)CN(Cc2ccc(C=C[C@@]3NNc4c3ccc([C@](C3)[C@]3(c3cc(*)ccc3N3*=I)C3=O)c4)cc2)C1 0.000 description 5
- JOCNOQUWDPPPRY-LYWAIKEGSA-N C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c5ccccc5N5)C5=O)ccc34)cc2)C1 Chemical compound C[C@H]1O[C@@H](C)CN(Cc2ccc(/C=C/c3n[nH]c4cc([C@H](C5)[C@]5(c5ccccc5N5)C5=O)ccc34)cc2)C1 JOCNOQUWDPPPRY-LYWAIKEGSA-N 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361892887P | 2013-10-18 | 2013-10-18 | |
| US61/892,887 | 2013-10-18 | ||
| PCT/CA2014/050952 WO2015054781A1 (en) | 2013-10-18 | 2014-10-03 | Treatment for pancreatic cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016533373A JP2016533373A (ja) | 2016-10-27 |
| JP2016533373A5 true JP2016533373A5 (https=) | 2017-11-09 |
| JP6525983B2 JP6525983B2 (ja) | 2019-06-05 |
Family
ID=52827497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524100A Expired - Fee Related JP6525983B2 (ja) | 2013-10-18 | 2014-10-03 | 膵癌の治療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9642856B2 (https=) |
| EP (1) | EP3057593B1 (https=) |
| JP (1) | JP6525983B2 (https=) |
| KR (1) | KR102195494B1 (https=) |
| CN (1) | CN105764515B (https=) |
| AU (1) | AU2014336917B2 (https=) |
| CA (1) | CA2927612C (https=) |
| EA (1) | EA030089B1 (https=) |
| ES (1) | ES2908200T3 (https=) |
| IL (1) | IL245037B (https=) |
| MX (1) | MX357763B (https=) |
| SG (1) | SG11201602882VA (https=) |
| WO (1) | WO2015054781A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2465971T3 (es) | 2009-04-06 | 2014-06-09 | University Health Network | Inhibidores de quinasa y método para tratar cáncer con los mismos |
| SI2556071T1 (sl) | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| HUE043194T2 (hu) | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
| WO2019046949A1 (en) | 2017-09-08 | 2019-03-14 | University Health Network | POLYTHERAPIES FOR INHIBITING KINASE 4 OF THE POLO TYPE |
| CA3137191A1 (en) | 2019-04-24 | 2020-10-29 | University Health Network | Crystal form s4 of the plk4 inhibitor (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6-yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
| JP7717842B2 (ja) | 2021-05-11 | 2025-08-04 | オリック ファーマシューティカルズ，インク． | ポロ様キナーゼ４阻害剤 |
| CN115677682B (zh) * | 2021-07-30 | 2023-07-18 | 上海齐鲁制药研究中心有限公司 | 螺环类plk4抑制剂及其用途 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US5182397A (en) | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| DE69734521T9 (de) | 1996-08-23 | 2006-12-07 | Sugen, Inc., South San Francisco | Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6133305A (en) | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| CA2383623A1 (en) | 1998-08-04 | 2000-02-17 | Sugen, Inc. | 3-methylidenyl-2-indolinone modulators of protein kinase |
| EP1165513A1 (en) | 1999-03-24 | 2002-01-02 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| JP2003535847A (ja) | 2000-06-02 | 2003-12-02 | スージェン・インコーポレーテッド | 蛋白質キナーゼ／ホスファターゼ阻害剤としてのインドリノン誘導体 |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| US20070167488A1 (en) | 2003-12-16 | 2007-07-19 | Leo Pharma A/S | Novel therapeutic use |
| US7309787B2 (en) | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US20070135509A1 (en) | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
| EP2036894A4 (en) * | 2006-06-30 | 2011-01-12 | Kyowa Hakko Kirin Co Ltd | AURORA INHIBITOR |
| EP2181108A2 (en) | 2007-06-12 | 2010-05-05 | Boehringer Ingelheim International GmbH | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases |
| JP2009173629A (ja) | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| EP2262499B1 (en) | 2008-03-11 | 2016-12-21 | University Health Network | Mk-0557 for use in the treatment of cancer |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| DE102008040187A1 (de) | 2008-07-04 | 2010-01-07 | Robert Bosch Gmbh | Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung |
| ES2465971T3 (es) | 2009-04-06 | 2014-06-09 | University Health Network | Inhibidores de quinasa y método para tratar cáncer con los mismos |
| WO2011069298A1 (en) | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP5056876B2 (ja) | 2010-03-19 | 2012-10-24 | Ｊｆｅスチール株式会社 | 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法 |
| SI2556071T1 (sl) | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| ES2706066T3 (es) * | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| KR102502745B1 (ko) | 2017-06-29 | 2023-02-23 | 옌타이 콴티시젼 다이애그노틱스 인크. | 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치 |
-
2014
- 2014-10-03 WO PCT/CA2014/050952 patent/WO2015054781A1/en not_active Ceased
- 2014-10-03 EA EA201690763A patent/EA030089B1/ru not_active IP Right Cessation
- 2014-10-03 KR KR1020167012617A patent/KR102195494B1/ko not_active Expired - Fee Related
- 2014-10-03 CA CA2927612A patent/CA2927612C/en active Active
- 2014-10-03 CN CN201480064033.0A patent/CN105764515B/zh not_active Expired - Fee Related
- 2014-10-03 US US15/029,269 patent/US9642856B2/en not_active Expired - Fee Related
- 2014-10-03 AU AU2014336917A patent/AU2014336917B2/en not_active Ceased
- 2014-10-03 MX MX2016004967A patent/MX357763B/es active IP Right Grant
- 2014-10-03 ES ES14853347T patent/ES2908200T3/es active Active
- 2014-10-03 SG SG11201602882VA patent/SG11201602882VA/en unknown
- 2014-10-03 EP EP14853347.4A patent/EP3057593B1/en active Active
- 2014-10-03 JP JP2016524100A patent/JP6525983B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-11 IL IL245037A patent/IL245037B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016533373A5 (https=) | ||
| Catalano et al. | Gastric cancer | |
| Nielsen et al. | A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan+/− targeted therapy | |
| JP2016538344A5 (https=) | ||
| JP2018529656A5 (https=) | ||
| JP2019523214A5 (https=) | ||
| JP2015513919A5 (https=) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2017517520A5 (https=) | ||
| AR094849A1 (es) | Terapia combinada que involucra anticuerpos dirigidos contra claudina 18.2 para el tratamiento de cáncer | |
| JP2016501221A5 (https=) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2015508103A5 (https=) | ||
| JP2017527582A5 (https=) | ||
| JP2016506413A5 (https=) | ||
| JP2015522522A5 (https=) | ||
| JP2018513155A5 (https=) | ||
| JP2017516827A5 (https=) | ||
| JP2013528215A5 (https=) | ||
| JP2019517507A5 (https=) | ||
| JP2016529236A5 (https=) | ||
| Shih et al. | Bozitinib, a highly selective inhibitor of cMet, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models | |
| JP2016540726A5 (https=) | ||
| JP2016522188A5 (https=) | ||
| JP2020500907A5 (https=) |